# One Scientist’s War To Understand Unregulated Drugs > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/one-scientists-war-to-understand-unregulated-drugs/ > **Published:** 2026-06-18T12:26:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:43-04:00 > **Clinical Summary:** Why cannabis product testing standards matter for clinical dosing accuracy and patient safety in cannabis medicine practice. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchHempSafetyPolicyIndustryPainAnxiety Why This Matters Clinicians need standardized cannabis testing data to provide patients with accurate information about potency, contaminants, and product safety since unregulated products may contain harmful substances or mislabeled cannabinoid levels. Understanding testing best practices helps clinicians counsel patients on quality assurance when cannabis is used therapeutically or recreationally, reducing risks from contamination and dosing errors. Federal research into hemp and cannabis testing establishes evidence-based quality standards that can inform clinical recommendations and patient safety protocols. Clinical Summary A scientist has undertaken research to establish standardized testing practices for cannabis and hemp products in response to quality and safety concerns in largely unregulated markets. The work, supported by federal funding, addresses the lack of consistent analytical standards across the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), where products often vary significantly in cannabinoid content, contaminant levels, and purity. These testing gaps create substantial clinical uncertainty, as physicians cannot reliably counsel patients on dosing or predict therapeutic or adverse effects when product composition is unknown or mislabeled. Standardized testing protocols would provide clinicians with accurate product information necessary for safe prescribing and would help patients make informed decisions about [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). This research contributes to establishing the scientific rigor and quality assurance that cannabis products require to be used responsibly in clinical practice, particularly as more states legalize [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). Clinicians should advocate for tested, labeled products with verified [cannabinoid profiles](https://cedclinic.com/cannabis-clinical-trials-mental-health-march-2026/) when discussing cannabis with patients, and remain aware that unregulated products remain a significant source of dosing variability and potential harm. Dr. Caplan’s Take “What strikes me about unregulated cannabis markets is that we’re essentially asking patients to self-experiment without reliable information about potency, contaminants, or consistency, which violates basic principles of informed consent. Standardized testing protocols backed by federal funding represent real progress toward bringing some scientific rigor to a space where anecdote and marketing have long outpaced evidence.” Clinical Perspective 💊 As cannabis products proliferate in largely unregulated markets, the quality and safety challenges documented in testing research have direct implications for clinical practice. Patients increasingly report [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during routine visits, yet healthcare providers often lack reliable data on product potency, contaminant profiles, or consistency between batches, making risk stratification and counseling difficult. The gap between what consumers believe they are purchasing and what laboratory analysis reveals—including variable cannabinoid concentrations and potential pesticide or microbial contamination—underscores why standardized testing frameworks matter for clinical decision-making. Clinicians should recognize that inconsistent product quality makes patient-reported dosing unreliable and complicates efforts to identify cannabis-related adverse effects or drug interactions in their populations. Advocating for transparent labeling and evidence-based testing standards in your jurisdiction, while educating patients about these limitations, represents a practical step toward safer [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) conversations in clinical settings. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20One%20Scientist%27s%20War%20To%20Understand%20Unregulated%20Drugs%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59605)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59605)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20One%20Scientist%27s%20War%20To%20Understand%20Unregulated%20Drugs%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59605)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://www.theassemblync.com/news/investigations/michelle-peace-hemp-drug-testing-lab/](https://www.theassemblync.com/news/investigations/michelle-peace-hemp-drug-testing-lab/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).